Document is current

Article History

Received: 10 December 2021

Revised: 20 February 2022

Accepted: 2 March 2022

First Online: 15 March 2022

Competing interests

: LCB declares the following relationships: Consulting with Seattle Genetics. SH, JAS, MH, YW, TO, LH, MA, CD, MRH, PP, JS, and KJW declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. JH is a consultant for or owns shares in the following companies: Kingmed, MoreHealth, OptraScan, Genetron, Omnitura, Vetonco, York Biotechnology, Genecode, VIVA Biotech and Sisu Pharma, and received grants from Zenith Epigenetics, BioXcel Therapeutics, Inc., and Fortis Therapeutics. TZ declares the following: Research funding: Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeneron, Mirati Therapeutics, Janssen, AstraZeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, Astellas. Speaker: Sanofi-Aventis (end 2020), Genomic Health (end 2020). Advisory Board: Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, Amgen, BMS, Pharmacyclics, SeaGen, Calithera, Eisai, Aveo. Consultant: Pfizer, MJH Associates, Vaniam Group, Aptitude Health, Nanorobotics (spouse). Employee: Capio Biosciences (spouse), Archimmune Therapeutics (spouse). Stockholder: Capio Biosciences, Archimmune Therapeutics, Nanorobotics (all spouse). DJG declares the following relationships: Acerta Pharmaceuticals—Research, American Association for Cancer Research—Sr Editor, Astellas—Consultant, Research, Advisory Board, AstraZeneca—Consultant, Advisory Board, Axess Oncology—Independent Contractor, Bayer H/C Pharmaceuticals—Research, Consultant, Speaker, Honorarium, Travel accommodations, SC, BMS—Consultant, Research, Steering Committee, Calithera—Research, Capio Biosciences—Scientific Advisory Board, EMD Serono—Honorarium, Exelixis, Inc—Research, Consultant, Speaker, Honorarium, Travel accommodations, Flatiron—Consultant, Ipsen—Honorarium, Janssen Pharmaceuticals—Research, Consultant, Independent Data Monitoring Committee (IDMC), Leidos Biomedical Research—Consultant, Merck Sharp & Dohme—Consultant, Michael J Hennessey Associates—Honorarium, Consultant, Millennium Medical Publishing, Clinical Advances in Hematology & Oncology—Co-Editor-in-Chief, Modra Pharmaceuticals B.V.—Advisory Board, Myovant Sciences, Inc—Consultant, Nektar Therapeutics—Steering Committee, Novartis—Research, Physician Education Resource LLC—Consultant, Pfizer—Research, Consultant, Steering Committee, Honorarium, Sanofi—Research, Consultant, Speaker, Honorarium, Travel accommodations, UroGPO—Honorarium, UroToday—Honorarium, Travel accommodations, Vizuri Health Sciences, LLC—Consultant, NCI—Steering Committee. AJA declares the following relationships: paid consultant with Pfizer, Astellas, Janssen, Bayer, AstraZeneca, Epic Sciences, Exelixis, Myovant, NCCN, BMS, Forma and Merck and receives research funding (to his institution) from Amgen, Forma, Celgene, Pfizer, Astellas, Janssen, Bayer, Dendreon, Novartis, Genentech/Roche, Merck, BMS, AstraZeneca, Constellation, Beigene. Steering committee for Astellas/Pfizer, AstraZeneca, BMS, Merck, Myovant.

Free to read: This content has been made available to all.